HS-10241

HS-10241 is an orally bioavailable, highly potent, and selective small molecule inhibitor of the proto-oncogene protein c-Met (hepatocyte growth factor receptor; HGFR), developed for the treatment of advanced solid tumors, particularly non-small cell lung cancer (NSCLC). By binding to and inhibiting c-Met kinase activity, HS-10241 prevents phosphorylation and disrupts downstream signaling pathways involved in tumor growth and survival. Preclinical studies have demonstrated strong antitumor activity both in vitro and in vivo. Clinical trials have shown that HS-10241 is well tolerated with promising efficacy, especially in patients with MET gene alterations or amplification. It is being investigated as monotherapy as well as in combination with EGFR inhibitors such as almonertinib to overcome resistance mechanisms following prior EGFR-TKI therapy.

Other names

c-Met inhibitor HS-10241